Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
7-Hydroxymitragynine (1) ·
Acacia confusa (1) ·
Amanita muscaria (1) ·
Anadenanthera colubrina (1) ·
Anadenanthera peregrina (1) ·
Ayahuasca (1) ·
Blue lotus (1) ·
Calea zacatechichi (1) ·
Datura (1) ·
Dextromethorphan / Quinidine (1) ·
Harmaline (1) ·
Harmine (1) ·
Hawaiian Baby Woodrose (1) ·
Iboga (1) ·
Kava (1) ·
ketamine (1) ·
Kratom (1) ·
lithium (1) ·
mescaline (1) ·
Mitragynine (1) ·
Morning Glory (1) ·
Myristicin (1) ·
opium (1) ·
Peyote (1) ·
Psilocybin mushrooms (1) ·
Psychotria viridis (1) ·
Salvia divinorum (1) ·
San Pedro cactus (1) ·
Syrian rue (1) ·
Tetrahydroharmine (1) ·
Tramadol / Acetaminophen (1) ·
Yopo (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5HT1a (1) ·
Apomorphine and nuciferine; dopaminergic activity (1) ·
Contains atropine, scopolamine, hyoscyamine (1) ·
Contains bufotenin and DMT (1) ·
Contains harmine, harmaline, tetrahydroharmine (1) ·
Contains ibogaine; kappa-opioid agonist (1) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Contains muscimol and ibotenic acid (1) ·
Contains psilocybin and psilocin (1) ·
Contains salvinorin A (1) ·
DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) ·
DMT-containing plant used in psychedelic preparations (1) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Mechanism incompletely understood (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
NMDA-receptor antagonism (1) ·
Partial MAOI; anticholinergic effects (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Potent mu-opioid receptor agonist (1) ·
Reversible MAO-A inhibitor; beta-carboline (1) ·
Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) ·
Source of DMT-class tryptamines (1) ·
Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) ·
Source of [[DMT|N,N-dimethyltryptamine]] (1) ·
TBD (1) ·
Weak serotonin reuptake inhibitor; beta-carboline (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) ·
µ-opioid agonism (1)
uses:
starting dose:
preparations:
fda max:
duration:
halflife:
None (30) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1)
bioavailability:
pregnancy:
None (30) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (30) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 32 results in range #1 to #32.